BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody in Adult Participants With Previously Treated B-cell Malignancies

Eli Lilly and Company

Summary

The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Must have a diagnosis of either follicular lymphoma or diffuse large B-cell lymphoma. * Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Estimated life expectancy of greater than or equal to (≥)12 weeks as judged by the Investigator. * Participants with select tumor types must have measurable or assessable disease as defined below: * Participants with lymphoma must have at least 1 bi-dimensionally measurable lesion or in the absence of measurable lymphadenopathy, documentation of bone marrow involvement. * Participants with Wald…

Locations (51)

City of Hope
Duarte, California
University of Colorado Denver - School of Medicine - Anschutz Medical Campus
Aurora, Colorado
Colorado Blood Cancer Institute
Denver, Colorado
Yale University School of Medicine - Yale Cancer Center
New Haven, Connecticut
The University of Chicago Medical Center (UCMC)
Chicago, Illinois
University of Iowa
Iowa City, Iowa

Summary

Eligibility

Interventions

Locations (51)